title: Pharmacokinetics of cadralazine in a large group of hypertensive patients chronically treated with cadralazine: advantage over a conventional study in a small group of patients.
abstract: The concentrations of cadralazine in plasma were studied in 101 hypertensive patients treated with oral doses of 10, 15, or 20 mg of cadralazine once daily. Most of the patients received additionally a beta-blocking drug (n = 87) and a diuretic (n = 52). Few blood samples were collected in each patient on several occasions during the treatment, which usually lasted for more than 6 months. No accumulation of cadralazine in plasma occurred in any of the patients and the maximum concentrations were similar to those recorded in a small sample of healthy volunteers. The terminal half-life of elimination (3.6 h) was longer than that observed in healthy subjects (approximately 2.5 h). Conversely, the total clearance (197 ml/min) was lower (285 ml/min in healthy). The half-life and the total clearance in plasma were not dose dependent. In the patients treated for more than 6 months, no change in the pharmacokinetics of cadralazine was detected. The description of the distribution of concentrations showed that one-half of the patients behaved similarly to healthy subjects concerning half-life and total clearance. The other half presented a slower elimination of the drug (t 1/2 = 4.4 h and ClT = 130 ml/min) and these patients were significantly older (p = 0.01) than the former. This suggests that special attention should be paid to old hypertensive patients when a dose higher than 15 mg once daily is prescribed. Though concentrations were proportional to the dose, the body weight was not found to be a determining factor for dose adjustment.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Biopharmaceutical Research Center, Laboratoires Ciba-Geigy, Rueil-Malmaison, France.
authors.forename: J B
authors.initials: JB
authors.lastname: Lecaillon
authors.forename: J P
authors.initials: JP
authors.lastname: Dubois
authors.forename: T
authors.initials: T
authors.lastname: Darragon
authors.forename: M
authors.initials: M
authors.lastname: Motolese
authors.forename: A
authors.initials: A
authors.lastname: Racine
authors.forename: F
authors.initials: F
authors.lastname: Ducret
authors.forename: D
authors.initials: D
authors.lastname: Grouberman
authors.forename: D
authors.initials: D
authors.lastname: Cordonnier
authors.forename: J
authors.initials: J
authors.lastname: Chanard
authors.forename: M
authors.initials: M
authors.lastname: Glorioso
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001835:Body Weight; D002851:Chromatography, High Pressure Liquid; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011724:Pyridazines / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use
chemical_list: D000959:Antihypertensive Agents; D011724:Pyridazines; C031877:cadralazine